Archives: Speakers

Lesley Fitton

Having graduated from University with a degree in biochemistry , I have worked in the pharmaceutical industry for 30+ years most of these in clinical development. For the last 10 years I have had the role of Director of clinical operations within the anti-infectives portfolio first at AZ then latterly at a small biotech company F2G. I have also had a similar tole within the oncology and CNS portfolio and have worked across all phases of development from FTiM to phase 4 and post approval commitment studies. I am very interested in the difference between small and large pharma and the way these different entities interact and partner with CROs.

Dr Sarah Johnson

Sarah Johnson, PhD, VP, Head of Clinical Affairs for QIAGEN, leads a team of clinical specialists to deliver global multi-site clinical studies on MDx and CDx products.  As an expert in clinical affairs, diagnostics and women’s health, she has >40 peer reviewed publications in the diagnostics field.  Previously she has headed up regulatory affairs, medical affairs and research in other diagnostic companies, and has been a UK company director.  She has a PhD in cell biology and was a qualified medical geneticist.

Douglas Blakey

Reporter, dep editor and then editor of Retail Banker International at Timetric Financial Services since 2005. Chairman of The Digital Banking Club  www.thedigitalbankingclub.com since Jan 2013
Contributor to The New Statesman since March 2012
http://www.newstatesman.com/writers/38379

Twitter @retailbanker and @douglasblakey  Previously editor of Bank Marketing International.